FDA
-
-
-
-
-
-
-
IMAC (IMAC) Receives FDA Authorization to Initiate Clinical Study of Its Umbilical Cord-Derived Allogenic Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson's Disease
-
-
-
-
-
-
-
IMAC’s BioFirma Subsidiary Announces Registered Status with U.S. Food and Drug Administration
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

